Clinical Trial Update: A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection [Phase 2]

View source ↗

Summary

Phase 2 study evaluating thymoglobulin with reduced steroid doses to prevent rejection in kidney transplant recipients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplant Rejection

Drugs mentioned

• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Renal Transplantation, Graft Rejection | Phase 2 | Status: COMPLETED